Skin News and Research

RSS

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Key facts about polycystic ovary syndrome

September marks Polycystic Ovary Syndrome (PCOS) awareness month and with this condition affecting millions of women in the world, there are some key facts about the condition to highlight that can affect a women's fertility when suffering with the disorder.

6 Sep 2012

Study examines relationship between life events and survival after diagnosis of melanoma

A study that is published in the last issue of Psychotherapy and Psychosomatics examines the relationship between life events and survival after diagnosis of melanoma, a life-threatening cancer of the skin. Negative, undesirable events are important for health outcomes.

6 Sep 2012

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

A team of scientists led by a bone marrow transplant researcher at Fred Hutchinson Cancer Research Center has shed new light on why most bone marrow transplant patients who receive tissue-matched cells from unrelated donors still suffer acute graft-versus-host disease (GVHD).

6 Sep 2012

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.

6 Sep 2012

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Kinetic Concepts, Inc. (KCI) announced today the U.S. launch of the Skin IQ 1000 Microclimate Manager (MCM) by its Therapeutic Support Systems (TSS) business.

6 Sep 2012

Arsenic induces acute promyelocytic leukemia remission

Elderly patients with acute promyelocytic leukemia have a high rate of response to arsenic trioxide, say researchers who believe the drug should be a first-line treatment in this population.

5 Sep 2012

Complex spine minimally invasive retractor system launched by K2M

K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced the launch of the SERENGETI® Complex Spine Minimally Invasive Retractor System at the Scoliosis Research Society (SRS) 47th Annual Meeting in Chicago.

5 Sep 2012

BioReliance introduces Reconstructed Skin Micronucleus Assay to detect DNA damage

Sigma-Aldrich Corporation today announced that its recent acquisition, BioReliance, the biopharma and early development services business under SAFC, will introduce a new assay to detect DNA damage from products with dermal routes of exposure. The Reconstructed Skin Micronucleus (RSMN) Assay represents the first commercial offering of a Genetic Toxicology assay using three-dimensional tissue models.

5 Sep 2012

Sleep apnoea severity associated with increased cancer mortality

Sleep apnoea severity has been associated with increased cancer mortality in a new study.

5 Sep 2012

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.

5 Sep 2012

Thermal imaging technology to identify drunks

Thermal imaging technology might one day be to identify drunks before they become a nuisance in bars, airports or other public spaces. Georgia Koukiou and Vassilis Anastassopoulos of the Electronics Laboratory, at University of Patras, Greece, are developing software that can objectively determine whether a person has consumed an excessive amount of alcohol based solely on the relative temperature of different parts of the person's face.

5 Sep 2012

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

The primitive stem cell state we created is called an “induced pluripotent stem cell” (iPSC). iPSC are a new, unique, and artificially-created type of stem cell that were first described in 2006 by a Japanese scientist named Shinya Yamanaka.

4 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

Parkinson disease may share common pathogenic mechanisms with some cancers

A study that used a Utah genealogic database and a statewide cancer registry to examine the relationship between Parkinson disease (PD) and cancer suggests an increased risk of prostate cancer and melanoma in patients with PD and their relatives, according to a report published Online First by Archives of Neurology, a JAMA Network publication.

4 Sep 2012

Novel scoring system shows sclerotherapy improves pain of venous malformation

Ethanol sclerotherapy reduces the signs and symptoms of venous malformation in the majority of patients after approximately two sessions, report Japanese researchers who used a novel scoring system to evaluate treatment outcomes.

3 Sep 2012

Inhaled steroid drugs slow growth in children with asthma

Children who use inhaled steroid drugs for asthma end up slightly shorter at their full adult height than children who don't use the drugs, new results from a comprehensive asthma study show.

3 Sep 2012

IOMA launches new skincare mobile app for women

Always closer to women and forever listening to their needs, IOMA launches a mobile application to help women better know their skin and help fulfill all their beauty desires.

3 Sep 2012

New drug combines photothermia and chemotherapy to help fight cancer

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

3 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012

Skin News and Research

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Key facts about polycystic ovary syndrome

Study examines relationship between life events and survival after diagnosis of melanoma

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Arsenic induces acute promyelocytic leukemia remission

Complex spine minimally invasive retractor system launched by K2M

BioReliance introduces Reconstructed Skin Micronucleus Assay to detect DNA damage

Sleep apnoea severity associated with increased cancer mortality

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

Thermal imaging technology to identify drunks

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

Parkinson disease may share common pathogenic mechanisms with some cancers

Novel scoring system shows sclerotherapy improves pain of venous malformation

Inhaled steroid drugs slow growth in children with asthma

IOMA launches new skincare mobile app for women

New drug combines photothermia and chemotherapy to help fight cancer

Potential new COPD drug

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News